Chronic MH has distinct features on OCT

Article

Chronic macula holes (MHs) have distinct features compared to those of acute symptomatic MH on OCT findings.

Chronic macula holes (MHs) have distinct features compared to those of acute symptomatic MH on OCT findings, according to a paper published in Retina.

Dr C. Yun et al., Department of Ophthalmology, Korea University College of Medicine, Seoul, South Korea, retrospectively reviewed OCT images of 13 eyes of 13 patients with chronic MH and 67 eyes of 67 patients classified as controls.

Chronic MH was identified as MH observed without undergoing surgical treatment for at least a year. The OCT parameters were compared between chronic and acute MH.

The basal hole diameter did not differ when chronic MH eyes and control eyes were compared. However, the minimum hole diameter of chronic MH was larger than the control diameters. Hole height and MH index were smaller in the chronic MH group, compared to the control group.

Only the chronic MH group presented with retinal pigment epithelial atrophy and intraretinal fluid was less frequently observed, compared to the control group. The findings could be useful for identifying the differences between chronic and acute MH.

To read the abstract please click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.